Analyst Conference Summaries

Biotechnology Investor Aids

Ionis Pharmaceuticals
IONS

conference date: February 21, 2024 @ 8:30 AM Pacific Time

Ionis: Price Slump Is An Opportunity To Buy The Pipeline [June 2, 2021, Seeking Alpha]

Ionis With Akcea: Still A Bargain [October 21, 2020 @ Seeking Alpha]

Ionis Is A Long On Neurological Medicines Pipeline [July 15, 2020 @ Seeking Alpha]

Ionis, Akcea Confirmation With Hypertriglyceridemia Results [January 28, 2020 @ Seeking Alpha]

older articles are below conference summary table

2023
Ionis
Q1 2023
Ionis
Q2 2023
Ionis
Q3 2023
Ionis
Q4 2023
May 3, 2023 Aug. 9, 2023 Nov. 2, 2023 Feb. 21, 2024
2022
Ionis
Q1 2022
Ionis
Q2 2022
Ionis
Q3 2022
Ionis
Q4 2022
May 4, 2022 Aug. 9, 2022 Nov. 9, 2022 Feb. 22, 2023
2021
Ionis
Q1 2021
Ionis
Q2 2021
Ionis
Q3 2021
Ionis
Q4 2021
May 5, 2021 Aug. 4, 2021 Nov. 3, 2021 Feb. 24, 2022
2020
Ionis
Q1 2020
Ionis
Q2 2020
Ionis
Q3 2020
Ionis
Q4 2020
May 6, 2020 Aug. 5, 2020 Nov. 4, 2020 Feb. 24, 2021
2019
Ionis
Q1 2019
Ionis
Q2 2019
Ionis
Q3 2019
Ionis
Q4 2019
May 9, 2019 August 7, 2019 Nov. 6, 2019 Feb. 26, 2020
2018
Ionis
Q4 2018
May 4, 2018
August 7, 2018
Nov. 6, 2018
Feb. 27, 2019
2017
Q1 not available
August 8, 2017
Nov. 7, 2017
Feb. 28, 2018

Ionis Hits Huntington's Milestone [February 1, 2019 @ Seeking Alpha]

Ionis Rising on RNA Therapy Optimism [December 14, 2018 @ Seeking Alpha]

Ionis is a Buy on RNA Platform Pipeline [March 7, 2018 @ Seeking Alpha]

Akcea Undervalued as Commercial Launches Near [April 12, 2018 @ Seeking Alpha]

Ionis Pharmaceuticals (IONS) is a biotechnology company specializing in RNA antisense based therapies, including Spinraza. Akcea Therapeutics (AKCA) is majority-owned by Ionis.

Ionis Pharmaceuticals web site

Ionis Pharmaceuticals investor relations


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BLUE
 BMY
 CDTX
 CLDX
 FATE
 GILD
 GLYC
 ILMN
 INCY
 INO
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SAGE
 SANA
 SYRS
 VRTX
 VSTM
 WBA
     
 

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2024 William P. Meyers